Shanghai Henlius Biotech Inc

Shanghai Henlius Biotech Inc maintains a capital structure characterized by significant leverage and tight liquidity metrics. The company reports total assets of CNY 12.36 billion against total liabilities of CNY 8.40 billion, resulting in a debt-to-equity ratio of 0.91. Long-term debt stands at CNY 3.60 billion, which exceeds the total equity of CNY 3.96 billion. The current ratio is 0.71, indicating that current liabilities exceed current assets, a condition flagged as medium liquidity risk. Operating cash flow is positive at CNY 1.31 billion, but free cash flow is minimal at CNY 56.7 million due to substantial capital expenditures of CNY 1.20 billion. The net cash position is negative after subtracting total debt, highlighting reliance on external financing or asset liquidation for short-term obligations.

Profitability metrics demonstrate strong returns on capital despite the high valuation multiples. The company achieved a net income of CNY 827.0 million on revenue of CNY 6.67 billion, yielding a net margin of approximately 12.4%. Return on equity (ROE) is 20.88%, and return on assets (ROA) is 6.69%, indicating efficient use of equity and assets to generate profit. The gross profit of CNY 4.98 billion suggests a gross margin of roughly 74.8%, consistent with high-margin biotechnology products. However, the market prices these earnings at a premium, with a price-to-earnings (P/E) ratio of 45.68 and an EV/EBITDA of 45.26. The price-to-book ratio is 9.54, reflecting investor expectations for future growth rather than current book value.

Revenue concentration and geographic exposure details are not explicitly provided in the available segment or geography data. The company operates as a single entity in the biotechnology space, with no disclosed breakdown of revenue by product line or region in the current snapshot. The absence of segment data prevents a detailed analysis of revenue diversification, implying that performance is tied to the aggregate success of its biotechnology portfolio.

Growth trajectory analysis is limited by the absence of historical period data in the current input. The latest normalized period shows revenue of CNY 6.67 billion and net income of CNY 827.0 million. Without prior year or quarterly comparisons, year-over-year growth rates cannot be calculated. The substantial capital expenditure of CNY 1.20 billion suggests ongoing investment in capacity or R&D, which may drive future revenue growth but currently suppresses free cash flow.

Risk factors include medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which poses a refinancing risk if operating cash flows do not improve or if debt maturities approach. The current ratio of 0.71 further underscores the need for careful working capital management. Dilution risk is assessed as low, with basic and diluted shares outstanding being identical at 545.2 million, indicating no significant options or convertible securities currently impacting share count.

Recent events and market sentiment are reflected in analyst estimates. The mean price target is CNY 100.62, with a median of CNY 101.34, suggesting upside potential from the current market price of CNY 69.30. The mean recommendation is 1.80, leaning towards a buy, with one strong buy and four buy ratings, and no hold ratings. This positive analyst sentiment contrasts with the company's tight liquidity position, implying confidence in future cash flow generation or strategic initiatives.

Revenue grew at a 41.1% CAGR over four years, demonstrating strong top-line expansion momentum.

Analysts project 46.9% upside to a mean price target of 100.62, signaling significant undervaluation.

The company achieved positive free cash flow of 358 million CNY in fiscal year 2025.

Net income growth stalled at only 0.8% year-over-year, suggesting limited earnings expansion potential.

The company carries a medium liquidity risk flag, highlighting potential short-term financial stability concerns.

A medium credit risk flag suggests potential challenges in managing debt obligations or borrowing costs.

Revenue ¥6.67B, +16,5% YoY; Operating income −5,6% YoY.

• ▍Revenue ¥6.67B, +16,5% YoY
• ▍Operating income −5,6% YoY
• ▍Net income +0,8% YoY
• ▍Free cash flow −84,2% YoY
• ▍Net margin 12.4%

Revenue ¥5.72B, +6,1% YoY; Operating income +42,4% YoY.

• ▍Revenue ¥5.72B, +6,1% YoY
• ▍Operating income +42,4% YoY
• ▍Net income +50,3% YoY
• ▍Free cash flow +437,2% YoY
• ▍Net margin 14.3%

Revenue ¥5.39B, +67,8% YoY; Operating income +215,6% YoY.

• ▍Revenue ¥5.39B, +67,8% YoY
• ▍Operating income +215,6% YoY
• ▍Net income +178,5% YoY
• ▍Free cash flow +94,0% YoY
• ▍Net margin 10.1%

Revenue ¥3.21B, +91,1% YoY; Operating income +32,5% YoY.

• ▍Revenue ¥3.21B, +91,1% YoY
• ▍Operating income +32,5% YoY
• ▍Net income +29,4% YoY
• ▍Free cash flow +6,9% YoY
• ▍Net margin -21.6%

Revenue ¥1.68B; Operating income -¥871.9M.

• ▍Revenue ¥1.68B
• ▍Operating income -¥871.9M
• ▍Net margin -58.5%